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Background: The CXC chemokine ligand 12 (CXCL12)/stromal cell-derived factor-1 (SDF-1) and CXC receptor 4
(CXCR4) axis is involved in human colorectal cancer (CRC) carcinogenesis and can promote the progression of CRC.
Interaction between CRC cells and endothelium is a key event in tumor progression. The aim of this study was to
investigate the effect of SDF-1 on the adhesion of CRC cells.
Methods: Human CRC DLD-1 cells were used to study the effect of SDF-1 on intercellular adhesion molecule-1
(ICAM-1) expression and cell adhesion to endothelium.
Results: SDF-1 treatment induced adhesion of DLD-1 cells to the endothelium and increased the expression level
of the ICAM-1. Inhibition of ICAM-1 by small interfering RNA (siRNA) and neutralizing antibody inhibited
SDF-1-induced cell adhesion. By using specific inhibitors and short hairpin RNA (shRNA), we demonstrated that the
activation of ERK, JNK and p38 pathways is critical for SDF-1-induced ICAM-1 expression and cell adhesion.
Promoter activity and transcription factor ELISA assays showed that SDF-1 increased Sp1-, C/EBP-β- and NF-κB-DNA
binding activities in DLD-1 cells. Inhibition of Sp1, C/EBP-β and NF-κB activations by specific siRNA blocked the
SDF-1-induced ICAM-1 promoter activity and expression. The effect of SDF-1 on cell adhesion was mediated by the
CXCR4.
Conclusion: Our findings support the hypothesis that ICAM-1 up-regulation stimulated by SDF-1 may play an
active role in CRC cell adhesion.
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Transcriptional regulationBackground
Colorectal cancer (CRC) is one of the most common
malignancies and is the fourth leading cause of cancer
death worldwide. Death due to colorectal cancer usually
results from metastatic spread of cancer cells [1]. Che-
mokines play a pivotal role in tumor progression be-
cause they may affect growth, adhesion and metastasis
of tumor cells [2,3]. CXC chemokine ligand 12* Correspondence: cnchen@mail.ncyu.edu.tw
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reproduction in any medium, provided the or(CXCL12)/Stromal cell-derived factor (SDF-1) is a mem-
ber of the CXC chemokine family, which plays an im-
portant role in chemotaxis, haematopoiesis, angiogenesis
and tumor spread and metastasis [4,5]. SDF-1 is
expressed in several cancer cells and is involved in
tumor cell migration and metastasis [6,7]. Several studies
have indicated that CRC cells promoted their survival
and migration to distant tissues by interaction between
SDF-1 and its specific receptor, CXC receptor 4
(CXCR4). The higher expression of CXCR4 in tumor tis-
sue correlates with poor prognosis and poor survival in
CRC patients [8,9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cell detachment from the primary carcinoma, but is
also involved in cell attachment to distant tissue [10].
The maintenance and promotion of cell adhesion are
particularly important processes in CRC progression
and metastasis. The intercellular adhesion molecule-1
(ICAM-1) is a member of the immunoglobulin (Ig)
gene superfamily of adhesion molecules. It is involved
in cancer cell adhesion and in the immune responses
of tumors [11,12]. The interaction between ICAM-1
and its specific ligand may facilitate adhesion of cancer
cells to the vascular endothelium and subsequently in
the promotion of metastasis. It has been reported that
the serum level of soluble (s)ICAM-1 is elevated in
patients with cancers [13]. High serum levels of
sICAM-1 have been shown to be correlated with
tumor progression in cases of CRC and associated
with liver metastasis [14,15]. Normal colon tissues do
not express ICAM-1, but this adhesion molecule can
be up-regulated on malignant transformation [16]. Sev-
eral studies also suggest that ICAM-1 plays an import-
ant role in CRC progression and metastasis [17-19]. It
has been demonstrated that SDF-1 effectively induced
the expression of urokinase plasminogen activator in
CRC cells [20]. In addition, SDF-1 has been implicated
in integrin-mediated adhesion in lung cancer and renal
cancer cells [21-23]. SDF-1–mediated cell adhesion via
ICAM-1 has also been reported in leukemia cells [24].
Firm cell adhesion between CD34+ cells and endothelial
cells is reported to occur when ICAM-1 and SDF-1 are
co-immobilized [25]. However, it is not clear whether
the regulation of ICAM-1 expression and cell adhesion
are mediated by SDF-1 in colorectal cancer cells.
Mitogen-activated protein kinases (MAPKs) are known
as major signaling pathways that play an essential role in
the development of inflammation and cancer [26]. Fur-
thermore, they have been reported to be involved in can-
cer cell pathological functions, including invasion and
angiogenesis [27]. In the present study, we show that
SDF-1 induces ICAM-1 expression in colorectal cancer
DLD-1 cells. Our data indicate that the SDF-1-induced
increase of ICAM-1 expression and cell adhesion is
mediated through the ERK, JNK and p38 intracellular
signaling cascades, and the transcription factors Sp1,
C/EBP-β and NF-κB. Our findings provide evidence of
the molecular mechanisms by which SDF-1 induces
ICAM-1 expression in colorectal cancer cells.
Methods
Materials
All culture materials were purchased from Gibco (Grand
Island, NY, USA). PD98059 (ERK inhibitor), SP600125
(JNK inhibitor), and SB203580 (p38 inhibitor) were pur-
chased from Calbiochem (La Jolla, CA). Polyclonal anti-ICAM-1 and anti-CXCR4 neutralizing antibody were
obtained from R & D Systems (Minneapolis, MN).
Mouse monoclonal antibodies (mABs) against ERK2,
JNK1, phospho-ERK1/2, phospho-JNK1/2, NF-κB p65,
Sp1, and C/EBP-β were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Rabbit polyclonal anti-
bodies against p38 and mouse monoclonal phospho-p38
antibody were purchased from Cell Signaling Technol-
ogy (Beverly, MA). ERK, JNK, and p38 shRNA and con-
trol shRNA (scrambled negative control containing
random DNA sequences) were purchased from the Na-
tional RNAi Core Facility in Academic Sinica, Taipei,
Taiwan. The NF-κB p65, Sp1, and C/EBP-β-siRNA and
control siRNA (scrambled negative control containing
random DNA sequences) were purchased from Invitro-
gen (Carlsbad, CA). AMD3100 (CXCR4 inhibitor) and
all other chemicals of a reagent grade were obtained
from Sigma (St. Louis, MO).
Cell culture
The colon cancer DLD-1 and SW48 cell lines were pur-
chased from the Bioresources Collection and Research
Center (BCRC) of the Food Industry Research and De-
velopment Institute (Hsinchu, Taiwan). Cells were main-
tained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin in a CO2 incubator at 37°C.
Human umbilical vein endothelial cells (HUVECs)
were isolated by collagenase digestion. Briefly, human
umbilical cords were washed, filled with 0.1% collage-
nase, and incubated at 37°C for 10 min. The suspension
of ECs collected was centrifuged for 10 min at 1200 × g.
The pellet was resuspended in M199 supplemented with
penicillin/streptomycin and 20% FBS, after which the
cells were plated onto cell culture dishes. Cultures were
maintained at 37°C in a humidified atmosphere contain-
ing 5% CO2. HUVECs of passage 2 were used for
experiments.
Flow cytometry analysis
The expressions of CXCR4 and ICAM-1 on the surface
of DLD-1 cells were measured by indirect immunofluor-
escence using flow cytometry and the mouse monoclo-
nal antibody (20 μg/mL; R&D) against CXCR4 and
ICAM-1 [28].
Cell adhesion assay
Adherence of DLD-1 and SW48 cells to HUVECs was
determined as described previously [29]. Before the ad-
hesion experiments, cells were cultured in low-serum
medium (0.5% FBS) for 12 h and then treated with SDF-
1 (10 ng/mL) for 4 h and labeled with 1, 10-dioctadecyl-
3, 3, 30, 30-tetramethylindocarbocyanine (DiI; Molecular
Probes, Eugene, OR) for 20 min. The labeled cells
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for 1 h. In parallel experiments, DLD-1 cells were
treated with specific inhibitors or transfected with spe-
cific shRNAs during SDF-1 stimulation. Non-adherent
cells were removed by washing with PBS. The adher-
ent cancer cells on the EC surface were identified and
counted in 10 randomly selected microscopic fields
(1.37 mm × 1.07 mm) under a Nikon Ti-E inverted
epifluorescence microscope with ×10 objective, and
the adhesion was expressed as a multiple compared to
the controls. To determine the role of CXCR4 and
ICAM-1 in the adhesion of DLD-1 and SW48 cells to
HUVECs, CRC cells were pre-incubated with 20 μg/mL of
anti-human CXCR4 and ICAM-1 antibodies (R&D) for
30 min, pretreated with AMD3100, or transfected with
the ICAM-1 siRNA prior to the adhesion assay.
Real-time quantitative PCR
Real-time PCR of three transcripts was performed using
an ABI Prism 7900HT with the FastStart DNA SYBR
Green I kit (Roche). The designed primers in this study
were: ICAM-1 forward primer, 50- GTGAC ATGCA
GCACC TCCTG-30; ICAM-1 reverse primer, 50- TCCAT
GGTGA TCTCT CCTCA-30; 18S rRNA forward primer,
50-CGGCG ACGAC CCATT CGAAC-30, 18S rRNA re-
verse primer, 50-GAATC GAACC CTGAT TCCCC
GTC-30. Quantification was performed using the 2−ΔΔCt
method [30]. All samples were measured in duplicate.
The average value of both duplicates was used as the
quantitative value.
ELISA for cell surface ICAM-1 expression
ICAM-1 expression on the cancer cell surface was mea-
sured by cell surface ELISA as previously described
[29]. Briefly, DLD-1 cells cultured in 96-well plates were
fixed by 4% paraformaldehyde. Cell surface ICAM-1 ex-
pression was assessed using the mouse anti-human
ICAM-1 mAb, followed by a horseradish-peroxidase-
conjugated secondary antibody. The absorbance of each
well was measured at 490 nm after the reactions were
stopped.
Western blot analysis
Samples were lysed with a buffer containing 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, and a protease in-
hibitor mixture (PMSF, aprotinin and sodium orthovana-
date). Protein concentration was determined using the
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Equal
amounts of total proteins were separated by SDS-
polyacrylamide gel electrophoresis (PAGE) (10% run-
ning, 4% stacking), transferred onto a nitrocellulose
membrane, and analyzed using the designated antibodies
and the Western-Light chemiluminescent detection sys-
tem (Bio-Rad).shRNA and siRNA transfection
For shRNA transfection, DLD-1 cells were transfected
with the designated MAPK shRNA plasmids by using
shRNA plasmid transfection reagent (Santa Cruz). For
siRNA transfection, DLD-1 cells were transfected with
the specific NF-κB p65, Sp1-1, and C/EBP-β-siRNA or
control siRNA by using an RNAiMAX transfection kit
(Invitrogen).Luciferase assays
Human ICAM-1 promoter constructs containing
−537/+16, -413/+16, -323/+16, -245/+16, -134/+16, and
−88/+16 of ICAM-1 5'-flanking DNA linked to the fire-
fly luciferase reporter gene of plasmid pGL4 (Promega,
Madison, WI) were used. DNA plasmids at a concentra-
tion of 1 mg/ml were transfected into DLD-1 cells by
Lipofectamine (Gibco). The pSV-β-galactosidase plasmid
was cotransfected to normalize the transfection effi-
ciency. Values obtained were normalized to the levels of
β-galactosidase in the cell lysates. β-galactosidase activ-
ities were determined with an assay kit and exhibited
<20% variation between samples.Transcription factor assays (TF ELISA assays)
Nuclear extracts of cells were prepared by nuclear pro-
tein extract kits (Panomics, Redwood City, CA). Equal
amounts of nuclear proteins were used for quantitative
measurements of NF-κB p65, Sp1 and C/EPB-β activation
using commercially available ELISA kits (Panomics).Chromatin immunoprecipitation assay (ChIP)
After cross-linking with 1% formaldehyde, the cells were
centrifuged and then resuspended in a lysis buffer for
three times of sonication of 15 sec each. Supernatants
were recovered by centrifugation. Aliquots of the pre-
cleared sheared chromatin were then immunoprecipi-
tated using 2 μg antibodies against IgG, NF-κB p65, Sp1
and C/EPB-β. The resulting DNA was used for PCR ana-
lysis, and the amplified DNA fragments were visualized
on an agarose gel. The human ICAM-1 promoter region
−305/-91 was amplified with the PCR primer pairs
50-ACCTT AGCGC GGTGT AGACC-30 and 50-CTCCG
GAACA AATGC TGC-30.Statistical analysis
The results are expressed as the mean ± standard error
of the mean (SEM). Statistical analysis was determined
using an independent Student t-test for two groups of
data and analysis of variance (ANOVA) followed by
Scheffe’s test for multiple comparisons. P values less
than 0.05 were considered significant.
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Effect of SDF-1 on adhesion of CRC cells to HUVECs
In order to quantify the adhesion of the CRC cells to
HUVECs, DLD-1 and SW48 cells were treated with dif-
ferent doses of SDF-1 (0–50 ng/mL) for 4 h and then la-
beled with DiI. The labeled cells were seeded onto the
HUVEC monolayers and co-cultured for 1 h. After re-
moval of the non-adherent cells, the remaining adherent
cells were evaluated. SDF-1 stimulation induced
increased adherence of DLD-1 and SW48 cells to
HUVECs in a dose-dependent manner (Figure 1A). To
assess the role of CXCR4 in SDF-1-induced cell adhe-
sion in DLD-1 and SW48 cells, we evaluated the effect
of CXCR4 inhibitor AMD3100 (100 nM) and CXCR4
neutralizing antibody on SDF-1-induced cell adhesion.
Pretreatment of AMD3100 and neutralizing antibody
against CXCR4 significantly inhibited the adhesion of
DLD-1 and SW48 cells to HUVECs (Figure 1B).
Pretreatment with AMD3100 could also inhibit adhe-
sion of DLD-1 cells treated with different doses of SDF-1
(Figure 1C). The effect of SDF-1 on CXCR4 expression inFigure 1 Effect of SDF-1 on CRC cell adhesion to HUVECs. All bar grap
calculated as the mean ± standard error of the mean (SEM) from five expe
*P < 0.05 versus CL. #P < 0.05 versus vehicle control (DMSO) or IgG-treated
different doses of SDF-1 were labeled with DiI and added to confluent mo
with SDF-1, DLD-1 and SW48 cells were pretreated with AMD3100, or incu
being kept as CL, DLD-1 cells were pretreated with AMD3100 for 1 h and w
shows the cell surface expression of CXCR4. DLD-1 cells were kept as CL or
or isotype-matched IgG served as a blank.DLD-1 cells was evaluated by flow cytometry assay using
CXCR4 antibody. As shown in Figure 1D, CXCR4 is
hardly expressed in DLD-1 cells, but cell surface expres-
sion is up-regulated by stimulation with SDF-1 for
4 h in DLD-1 cells.
Effect of SDF-1-induced ICAM-1 expression on adhesion
of DLD-1 cells to HUVECs
To investigate the role of ICAM-1 in the adhesion of
DLD-1 and SW48 cells to HUVECs, we blocked the
ICAM-1 function by using ICAM-1 neutralizing anti-
body and specific siRNA. SDF-1-induced adhesion of
DLD-1 and SW48 cells to HUVECs was significantly
inhibited by cells incubated with ICAM-1 neutralizing
antibody, or transfected with ICAM-1 siRNA, suggesting
a direct involvement of ICAM-1 in the adhesive inter-
action between CRC cells and HUVECs (Figure 2A). To
assess the role of CXCR4 in SDF-1-induced ICAM-1 ex-
pression in DLD-1 and SW48 cells, we evaluated the effect
of AMD3100 (100 nM) and CXCR4 neutralizing antibody
on SDF-1-induced ICAM-1 expression. Pretreatment ofhs represent the multiple increases over the control cells (CL),
riments. DLD-1 cells were kept as CL or stimulated with SDF-1 for 4 h.
cells with SDF-1 stimulation. (A) DLD-1 and SW48 cells treated with
nolayers of HUVECs for 1 h. (B) Before being kept as CL or stimulated
bated with neutralizing antibody against CXCR4 for 1 h. (C) Before
ere then stimulated with different doses of SDF-1. (D) Flow cytometry
stimulated with SDF-1. Cells were incubated with mAb against CXCR4
Figure 2 Effect of SDF-1 on ICAM-1 expression and cell adhesion of CRC cells. (A) SDF-1-stimulated DLD-1 and SW48 cells were treated
with isotype-matched IgG or 20 μg/mL neutralizing antibody against ICAM-1, or were transfected with control siRNA (si-CL) or si-ICAM-1, and
were then added to HUVECs for 1 h. (B) DLD-1 and SW48 cells were kept as CL or stimulated with SDF-1 for 4 h. Before being kept as CL or
stimulated with SDF-1, cells were pretreated with AMD3100 or incubated with neutralizing antibody against CXCR4 for 1 h. (C) Before being kept
as CL, DLD-1 cells were pretreated with AMD3100 for 1 h, and were then stimulated with different doses of SDF-1 for 4 h. All bar graphs
represent multiple increases of CL cells normalized to 18S rRNA. *p < 0.05 versus CL. #p < 0.05 versus IgG-treated, DMSO-treated, or si-CL-
transfected cells. (D) The ICAM-1 basal expression level of DLD-1 cells was analyzed by flow cytometry. Cells were incubated with mAb against
ICAM-1 or isotype-matched IgG served as a blank.
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markedly inhibited the expression of ICAM-1 mRNA
(Figure 2B).
Pretreatment with AMD3100 could also inhibit
ICAM-1 expression of DLD-1 cells treated with different
doses of SDF-1 (Figure 2C). The basal level of ICAM-1
expression in DLD-1 cells was evaluated by flow cytome-
try assay, as shown in Figure 2D.
SDF-1-induced ICAM-1 expression in DLD-1 and SW48
cells is dose- and time-dependent
Next, we examined the effect of SDF-1 on the ICAM-1
mRNA and cell surface protein expression by CRC
DLD-1 and SW48 cells. Cells were stimulated with SDF-1
(10 ng/mL) for the times indicated, or at different doses
(0–50 ng/mL) for 4 h. The changes in ICAM-1 expression
compared with the control cells at the same time points
were analyzed by real-time PCR, and cell surface ICAM-1
expression was detected by ELISA. The ICAM-1 mRNA
level began to increase after 1 h of SDF-1 treatment and
reached its highest level at 4 h (Figure 3A). The cell sur-
face ICAM-1 expression of DLD-1 and SW48 cells alsoincreased after 4 h of SDF-1 stimulation (Figure 3B).
The induction of ICAM-1 mRNA and cell surface
protein expression by SDF-1 stimulation was dose-
dependent (Figure 3C and 3D). In addition, SDF-1 also
induced an increase in total ICAM-1 protein expression
in DLD-1 cells in a time-dependent manner (Figure 3E).
ICAM-1 expression in the indicated times was inhib-
ited by DLD-1 cells treated with AMD3100 (Figure 3F).
In addition, SDF-1 induced only slight increases in the
DLD-1 VCAM-1 transcript level compared with un-
treated cells (Figure 3G).Effect of MAPK inhibitors on ICAM-1 mRNA expression
and cell adhesion in DLD-1 cells
To determine whether the SDF-1-induced ICAM-1 ex-
pression and cell adhesion to HUVECs is mediated
through the MAPK-dependent pathway, DLD-1 cells
were incubated with the specific inhibitor for ERK
(PD98059; 30 μM), JNK (SP600125; 20 μM), or p38
(SB203580; 10 μM) for 1 h before and during stimula-
tion with SDF-1. The SDF-1-1-induced ICAM-1 mRNA
Figure 3 Induction of ICAM-1 expression in DLD-1 and SW48 cells by SDF-1 stimulation. Samples were isolated at the indicated time
periods or doses. All bar graphs represent multiple increases of control cells (CL) normalized to 18S rRNA by real-time PCR analysis (A, C). The cell
surface ICAM-1 protein expression levels were determined by cell surface ELISA analyses (B, D). DLD-1 and SW48 cells were stimulated with 10
ng/mL SDF-1 for the times indicated (A, B), or stimulated with SDF-1 at various doses for 4 h (C, D). Data are shown as mean ± SEM. *P < 0.05
versus CL DLD-1 cells. (E) The expression of total ICAM-1 in DLD-1 cell lysate after SDF-1 stimulation for the times indicated was determined
using Western blotting. (F) Before being kept as CL, cells were pretreated with AMD3100 for 1 h and were then stimulated with SDF-1 for the
times indicated. *p < 0.05 versus CL. #p < 0.05 versus DMSO-treated cells. (G) DLD-1 cells were stimulated with SDF-1 for the times indicated. The
VCAM-1 mRNA expression level was determined by real-time PCR analysis normalized to 18S rRNA.
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to HUVECs (Figure 4C) was significantly inhibited by
PD98059, SP600125 and SB203580. To further confirm
the involvement of ERK, JNK, and p38, in the modula-
tion of ICAM-1 expression through SDF-1 stimulation,
we examined the effects of the specific shRNAs of these
signaling pathways on SDF-1-induced ICAM-1 expres-
sion in DLD-1 cells. The effectiveness of the silencing
was validated because ERK-, JNK-, and p38-shRNAs
(compared with control shRNA) caused an 85% reduc-
tion in ERK, JNK, and p38 protein expressions, respect-
ively (Figure 4A). The SDF-1-induced ICAM-1 mRNA
(Figure 4B) and cell surface ICAM-1 (Figure 4C) were
inhibited by transfection with ERK-, JNK-, and p38-
shRNAs. Furthermore, SDF-1-induced total ICAM-1
protein expression in DLD-1 cells was also inhibited by
cells pretreated with PD98059, SP600125 and SB203580
(Figure 4D).Our previous study demonstrated that the phosphoryl-
ation level of p38 in DLD-1 cells increased rapidly after
stimulation by SDF-1 [20]. In the present study, the
phosphorylation of ERK, JNK and p38 in DLD-1 cells
also increased after SDF-1 stimulation (Figure 4E). In
addition, the SDF-1–induced phosphorylation of ERK,
JNK and p38 in DLD-1 cells was inhibited by cells pre-
treated with AMD3100 (Figure 4E).
Sp1, C/EBP and NF-κB are essential for the SDF-1-
induction of human ICAM-1 expression
To identify the cis-acting elements in the ICAM-1 gene
promoter that mediate SDF-1-induced ICAM-1 tran-
scription, luciferase assays were conducted with the
ICAM-1 p537-Luc plasmid and several deletion promoter
constructs (Figure 5). In DLD-1 cells, the −537/+16
region of ICAM-1 directed maximum luciferase activity.
Sequence deletion from −245 to −134 caused the
Figure 4 MAPK pathways are required for SDF-1-induced ICAM-1 expression and cell adhesion. DLD-1 cells were kept as CL or stimulated
with 10 ng/mL SDF-1 for 4 h. Before being kept as CL or stimulated with SDF-1, DLD-1 cells were pretreated with PD98059 (PD), SP600125 (SP) or
SB203580 (SB) individually for 1 h, or transfected with control shRNA (sh-CL), or a specific shRNA of sh-ERK, sh-JNK or sh-p38. (A) The gene
silencing efficiency of 48-h transfection of shRNA on ERK, JNK, and p38 protein levels of DLD-1 cells. After 48 h of transfection, protein was
isolated and the ERK, JNK, and p38 expression was analyzed by Western blotting. (B) All bar graphs represent multiple increases of CL DLD-1 cells
normalized to 18S rRNA. (C) DLD-1 cells were stimulated with or without SDF-1 for 4 h, and were added to HUVECs for 1 h. The results are
shown as mean ± SEM. *P < 0.05 versus CL. #P < 0.05 versus vehicle control (DMSO) or control shRNA (sh-CL) with SDF-1 stimulation. (D) DLD-1
cells were kept as CL, pretreated with DMSO, PD98059 (PD), SP600125 (SP), or SB203580 (SB), and stimulated with SDF-1 for 4 h. The total ICAM-1
protein expressions were determined by Western blot analysis. (E) DLD-1 cells were kept as CL, pretreated with AMD3100, and stimulated with
SDF-1; the phosphorylation of ERK, JNK and p38 was determined by Western blotting.
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−88 nearly eliminated the activity (Figure 5).
To investigate whether SDF-1 can activate Sp1,
C/EBP-β, and NF-κB in DLD-1 cells, we performed
quantitative analysis of the Sp1, C/EBP-β, and NF-κB
p65 binding activities in vitro using TF ELISA kits from
Panomics. The treatment of DLD-1 cells with SDF-1
caused Sp-1- (Figure 6A), C/EBP-β- (Figure 6B) and NF-
κB p65-DNA (Figure 6C) binding activities to increase
after 1 h and remain elevated for at least 2 hours.
We further tested whether Sp1, C/EBP-β, and NF-κB
activation are involved in the signal transduction path-
way leading to the SDF-1 induction of ICAM-1promoter
activity. DLD-1 cells were transfected with siRNAs for
Sp1, C/EBP-β, or p65 followed by stimulation with SDF-1for 4 h. The Sp1, C/EBP-β, and NF-κB p65-specific siR-
NAs (compared with control siRNA) caused an 80% re-
duction in Sp1, C/EBP-β, and NF-κB p65 protein
expressions, respectively (Figure 6D). The SDF-1-induced
ICAM-1 p537-Luc promoter activity levels (Figure 6E)
were significantly down-regulated by the inhibition of spe-
cific siRNAs, indicating that Sp1, C/EBP-β, and p65 are
involved in the regulation of ICAM-1 gene expression.
These results were confirmed by ChIP analysis. Immuno-
precipitated chromosomal DNA with Sp1, C/EBP-β and
p65 antibodies was subjected to PCR, using primers
designed to amplify the ICAM-1 promoter region harbor-
ing these transcription factor binding sites. Sp1, C/EBP-β
and NF-κB were indeed found to bind the ICAM-1 pro-
moter region (Figure 6F).
Figure 6 Sp1-, C/EBP-β- and NF-κB-DNA binding activities induced by SDF-1 stimulation in DLD-1 cells. (A) Sp1 activation, (B) C/EBP-β
activation and (C) NF-κB p65 activation were determined by a TF ELISA assay. (D) The gene silencing efficiency of 48-h transfection of siRNA on
Sp1, C/EBP-β, and p65 protein levels of DLD-1 cells. After 48 h of transfection, protein was isolated and the Sp1, C/EBP-β, and p65 expression was
analyzed by Western blotting. (E) ICAM-1 mRNA and p537-Luc activity were determined in DLD-1 cells transfected with control siRNA (si-CL),
si-Sp1, si-C/EBP-β, or si-p65, and then stimulated with 10 ng/mL SDF-1 for 4 h. All bar graphs represent folds of CL DLD-1 cells, mean ± SEM.
*P < 0.05 versus CL. #P < 0.05 versus si-CL with SDF-1 stimulation. (F) ChIP assays were performed for Sp1, C/EBP-β, and NF-κB using p65 antibodies.
Figure 5 The roles of Sp1, C/EBP-β and NF-κB in SDF-1-induced ICAM-1 mRNA expression and promoter activity. The ICAM-1 promoter
p537-Luc plasmid and deletion promoter constructs. DLD-1 cells were cotransfected with 50-deletion constructs and stimulated with 10 ng/mL
SDF-1 for 4 h. ICAM-1 promoter activity was measured using a luciferase assay normalized to β-galactosidase activity and was shown to be
relative to that of DLD-1 cells transfected with p537-Luc (set to 100%). *P < 0.05 versus p537-Luc.
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induced ICAM-1 promoter activity
To evaluate whether the inhibition of ICAM-1 expres-
sion by MAPK signaling pathways occurs at the tran-
scriptional level, we studied the effects of MAPK
inhibitors and shRNAs on SDF-1-induced ICAM-1
p537-Luc promoter activity. Treatment of SDF-1
increased the luciferase activity compared with the un-
stimulated cells after normalization through transfection
control (Figure 7A). Pretreatment of cells with PD98059,
SP600125 and SB203580, or ERK-, JNK-, p38-shRNA
resulted in a marked inhibition of the SDF-1-induced
ICAM-1 promoter activity (Figure 7A).
To explore whether MAPKs activate the promoter
leading to ICAM-1 transcription via activations of Sp1,
C/EBP-β, and NF-κB, DLD-1 cells were pretreated with
MAPK inhibitors or transfected with MAPK shRNAs
followed by the SDF-1 treatment. The Sp1, C/EBP-β,
and NF-κB p65 activations were assessed using TF ELISA
kits. Pretreatment of cells with PD98059, SP600125 and
SB203580, or transfected with ERK-, JNK-, and p38-Figure 7 MAPK signaling pathways are involved in SDF-1-induced ICA
in DLD-1 cells pretreated with vehicle (DMSO), or PD98059 (PD), SP600125
shRNA (sh-CL), or a specific shRNAs of ERK (sh-ERK), JNK (sh-JNK) or p38 (sh
(C) C/EBP-β and (D) NF-κB p65 activation were determined by TF ELISA ass
SP600125 (SP) and SB203580 (SB) individually for 1 h, or transfected with sh
for 2 h. All bar graphs represent multiple increases of CL DLD-1 cells, mean
with SDF-1 stimulation. (E) DLD-1 cells were kept as CL or stimulated with
determined by Western blot analysis.shRNA significantly inhibited the SDF-1-induced Sp1-
(Figure 7B) and NF-κB p65-DNA (Figure 7D) binding
activity, whereas pretreatment of cells with PD98059
and SB203580, or transfected with ERK- and p38-
shRNA markedly inhibited the SDF-1-induced C/EBP-
β-DNA binding activity (Figure 7C). In addition, as
shown in Figure 7E, SDF-1 also induced degradation
of IκB protein in DLD-1 cells in a time-dependent
manner.
Discussion
The cell adhesion process plays a key role in tumor pro-
gression. Several adhesion molecules, including ICAM-1,
have been implicated in the tumor transformation and
metastasis via the mediating adhesion of cancer cells to
the vascular endothelium. This is an important proced-
ure for executing the subsequent steps of invasion and
survival of cancer cells [31]. It has been shown that CRC
metastases are related to the ability of cancer cells to ad-
here to the microvascular endothelium of the lung that
expresses the ligands for ICAM-1 on the tumor cellM-1 promoter activity. (A) ICAM-1 p537-Luc activity was determined
(SP), and SB203580 (SB) individually for 1 h, or transfected with control
-p38), and then stimulated with 10 ng/mL SDF-1 for 4 h. (B) Sp1,
ays in DLD-1 cells pretreated with vehicle (DMSO), or PD98059 (PD),
-CL, or sh-ERK, sh-JNK or sh-p38, and were then stimulated with SDF-1
± SEM. *P < 0.05 versus CL. #P < 0.05 versus vehicle control (DMSO)
SDF-1 for the times indicated, and the IκB protein expression was
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is expressed in CRC cells, and patients with higher
ICAM-1 levels in plasma reveal poor prognosis compared
to healthy controls [14,17,33]. In addition, up-regulation
of ICAM-1 expression is correlated with the cancer stage
and distant metastasis, suggesting that ICAM-1 plays a
central role in tumor progression and metastasis [34]. The
findings of the present study suggest that the expression
of ICAM-1 in DLD-1 cells may enhance their adhe-
siveness to HUVECs: 1) ICAM-1 was up-regulated by
SDF-1 stimulation in DLD-1 cells; 2) functional blockade
of ICAM-1 by siRNA and neutralizing antibody resulted
in markedly decreased adherence of DLD-1 cells to
HUVECs.
The expression of SDF-1 has been detected in several
cancer cells, indicating that these pathways may be im-
portant in the metastasis of tumor cells [35,36]. SDF-1
is a constitutively expressed and inducible chemokine
that modulates biological and physiological processes,
including embryonic development and organ homeosta-
sis [37]. Abnormal expression of SDF-1 has been
detected in various solid tumor tissues such as ovarian
cancer [38], breast cancer [39] and colorectal cancer
[40]. SDF-1 has been shown to promote the growth, in-
vasion and metastasis of CRC cells [41], implying that
SDF-1 plays a role in the progression of CRC; however,
the mechanisms of how SDF-1 stimulates metastasis of
CRC cells are not totally understood. In this study, we
evaluated the molecular mechanisms underlying the
roles of SDF-1 in modulating ICAM-1 expression and
cell adhesion to HUVECs in colon cancer cells. Our
results have demonstrated that SDF-1-induced expres-
sion of ICAM-1 expression is mediated by the MAPKs,
and downstream Sp1, C/EBP-β and NF-κB signaling
pathways.
The promoter region of the ICAM-1 gene has differ-
ent binding sites for various transcriptional factors
[42]. Previous studies have shown that the transcrip-
tion factors NF-κB, Sp1 and C/EBP-β can be activated
through the MAPK pathways in colorectal cancer cells
[20,43,44]. Regulation of gene expression through the
use of combinations of different transcription factors
has been observed [45,46]. It has been reported that
NF-κB and Sp1 can be activated by MAPK family
members, depending on the target gene in different
cells [47]. Patel et al. reported that MAPKs mediate
NF-κB and C/EBP-β activation, which leads to the
transcription of specific genes [48]. To evaluate the
signaling factors upstream of the activation of NF-κB,
Sp1 and C/EBP-β that lead to ICAM-1 transcriptional
activation in DLD-1 cells, we investigated the role of
MAPKs using specific inhibitors. In addition, we per-
formed TF ELISA assays to demonstrate that the regu-
lation of ICAM-1 gene expression in DLD-1 cells wasmediated by increased NF-κB p65, Sp1- and C/EBP-β-
DNA binding activities. Based on our results, we
propose a possible signal transduction pathway in
DLD-1 cells in which SDF-1 induces ERK, JNK and
p38 phosphorylation, which activates NF-κB, Sp1 and
C/EBP-β to lead to their binding to respective sites in
the ICAM-1 promoter, thus resulting in ICAM-1 tran-
scriptional activation.
Several studies have indicated that CRC cells express
CXCR4 and CXCR7, the receptors for SDF-1, and that
their survival and migration to distant tissues are pro-
moted by SDF-1 [41,49]. The binding of SDF-1 to
CXCR4 may affect several signaling pathways, which
can lead to multiple responses. Our previous study
revealed that the expression of urokinase plasminogen
activator in CRC DLD-1 cells by SDF-1 stimulation is
mediated by CXCR4 [20]. In order to analyze the role
of CXCR4 in ICAM-1 expression in human CRC cells,
we evaluated the effect of CXCR4 function-blocking
antibody on SDF-1–induced ICAM-1 expression. Our
results suggest that when DLD-1 cells encounter an ex-
ternal stimulus of SDF-1, SDF-1 induces ICAM-1 ex-
pression via CXCR4 up-regulation. Interestingly, DLD-1
cells did not express surface CXCR4 [50], but they had
abundant CXCR4 after SDF-1 stimulation, as deter-
mined by flow cytometry. Up-regulation of CXCR4 cells
is functionally important, as SDF-1-stimulated DLD-1
cells in contrast to control cells respond to SDF-1 by
inducing the ICAM-1 expression and adhering to
HUVECs in response to SDF-1. Previously it had been
reported that CXCR4 surface expression is hardly de-
tectable on neutrophils, but expression became appar-
ent gradually after incubation [51]. An alternative
possibility described recently postulates that CXCR7
may serve as a co-receptor for CXCR4 and mediate
SDF-1–induced intracellular signaling [52]. Several
studies have indicated that CRC cells also express
CXCR7, the receptors for SDF-1, and that their survival
and migration to distant tissues is promoted by SDF-1
[53]. However, the mechanisms of CXCR4 expression in
DLD-1 cells and the interaction between CXCR7
remains unknown, and further study is required to
identify whether SDF-1 affects CXCR7 function and
CXCR4 expression in CRC cells.
ICAM-1 expression modulates several cell functions
and processes that regulate the progression of malignan-
cies, including apoptosis, cell motility, invasion and
angiogenesis. It has been shown that ICAM-1 may sup-
port mesothelial adhesion of CRC cells [11]. Interaction
of ICAM-1 on vascular or lymphatic endothelial cells
has been found to promote the adhesion of lung cancer
and breast cancer cells [54,55]. In addition, ICAM-1
may be expressed by cancer cells themselves and con-
tribute to their invasiveness [56].
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In summary, our data contribute new information about
the mechanisms by which SDF-1 induces ICAM-1 ex-
pression and cell adhesion to the endothelium in colon
cancer cells.
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